Alcobra Company Profile (NASDAQ:ADHD)

About Alcobra

Alcobra logoAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADHD
  • CUSIP:
Key Metrics:
  • Previous Close: $1.22
  • 50 Day Moving Average: $1.32
  • 200 Day Moving Average: $2.65
  • 52-Week Range: $27,562,000.00 - $0.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.21
  • P/E Growth: 0.00
  • Market Cap: $34.18M
  • Outstanding Shares: 27,562,000
  • Beta: 1.33
Profitability:
  • Return on Equity: -38.21%
  • Return on Assets: -36.62%
Debt:
  • Current Ratio: 15.99%
  • Quick Ratio: 15.99%
Additional Links:
Companies Related to Alcobra:

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $2.16 (74.54% upside)

Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017Roth CapitalUpgradeNeutral -> Buy$4.00View Rating Details
1/18/2017Jefferies Group LLCDowngradeBuy -> Hold$6.00 -> $1.25View Rating Details
1/17/2017Cantor FitzgeraldSet Price TargetHold$2.00View Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00View Rating Details
1/17/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 -> $2.00View Rating Details
11/2/2016WBB SecuritiesUpgradeSell -> Hold$4.00 -> $1.90View Rating Details
10/28/2016Barclays PLCDowngradeEqual Weight -> Underweight$3.00 -> $2.00View Rating Details
9/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Alcobra (NASDAQ:ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/17/2017        
11/15/2016Q316($0.26)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/17/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.56)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.57)($0.57)ViewListenView Earnings Details
5/15/2014Q114($0.57)ViewN/AView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alcobra (NASDAQ:ADHD)
Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.56 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.19)($0.15)($0.17)
Q2 20163($0.22)($0.20)($0.21)
Q3 20163($0.29)($0.25)($0.27)
Q4 20163($0.36)($0.16)($0.27)
Q1 20172($0.25)($0.15)($0.20)
Q2 20172($0.23)($0.13)($0.18)
Q3 20172($0.18)($0.14)($0.16)
Q4 20172($0.19)($0.15)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Alcobra (NASDAQ:ADHD)
DateHeadline
globenewswire.com logoIMPORTANT ALCOBRA LTD. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a ... - GlobeNewswire (press release) (NASDAQ:ADHD)
globenewswire.com - February 25 at 3:17 PM
us.rd.yahoo.com logoIMPORTANT ALCOBRA LTD. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York on behalf of purchasers of Alcobra Ltd. (NASDAQ:ADHD)
us.rd.yahoo.com - February 24 at 8:20 PM
News IconWatching the Charts on Alcobra Ltd (ADHD) - The Standard (NASDAQ:ADHD)
6milestandard.com - February 24 at 3:19 PM
finance.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Alcobra Ltd. Investors and Encourages Investors to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 24 at 3:19 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 24 at 3:19 PM
globenewswire.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class ... - GlobeNewswire (press release) (NASDAQ:ADHD)
globenewswire.com - February 24 at 9:47 AM
4-traders.com logoGoldberg Law PC Announces Securities Class Action Lawsuit against Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
www.4-traders.com - February 23 at 8:21 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alcobra Ltd. Investors and Encourages Investors to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 23 at 8:21 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 23 at 8:21 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 23 at 3:20 PM
News IconGlobal Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pharmaceuticals (NASDAQ:ADHD)
www.medindia.net - February 21 at 5:46 AM
4-traders.com logoKhang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
www.4-traders.com - February 18 at 9:26 AM
prnewswire.com logoLifshitz & Miller LLP Files Class Action Lawsuit against Alcobra, Ltd. - PR Newswire (press release) (NASDAQ:ADHD)
www.prnewswire.com - February 17 at 6:47 PM
finance.yahoo.com logoLifshitz & Miller LLP Files Class Action Lawsuit against Alcobra, Ltd. (NASDAQ:ADHD)
finance.yahoo.com - February 17 at 6:47 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Alcobra, Ltd., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 17 at 6:47 PM
seekingalpha.com logoAlcobra (ADHD) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow (NASDAQ:ADHD)
seekingalpha.com - February 16 at 3:20 PM
us.rd.yahoo.com logoAlcobra Announces Fourth-Quarter and Full-Year 2016 Financial Results and Provides Corporate Update (NASDAQ:ADHD)
us.rd.yahoo.com - February 16 at 3:20 PM
biz.yahoo.com logoQ4 2016 Alcobra Ltd Earnings Release - 08:30 am ET (NASDAQ:ADHD)
us.rd.yahoo.com - February 16 at 3:20 PM
us.rd.yahoo.com logo7:08 am Alcobra provides Q4 results (NASDAQ:ADHD)
us.rd.yahoo.com - February 16 at 3:20 PM
globenewswire.com logoAlcobra Announces Fourth-Quarter and Full-Year 2016 Financial ... - GlobeNewswire (press release) (NASDAQ:ADHD)
globenewswire.com - February 16 at 6:32 AM
News IconAlcobra Ltd. (ADHD) likely to see bigger moves on its earnings ... - Post Analyst (NASDAQ:ADHD)
postanalyst.com - February 16 at 6:32 AM
sg.finance.yahoo.com logoAlcobra reports 4Q loss (NASDAQ:ADHD)
sg.finance.yahoo.com - February 16 at 6:32 AM
finance.yahoo.com logoEdited Transcript of ADHD earnings conference call or presentation 15-Feb-17 1:30pm GMT (NASDAQ:ADHD)
finance.yahoo.com - February 16 at 6:32 AM
News IconStock Levels in Review for Alcobra Ltd. (ADHD) - Rives Journal (NASDAQ:ADHD)
rivesjournal.com - February 14 at 1:38 AM
News IconShare Inspection for Alcobra Ltd. (ADHD) - Davidson Register (NASDAQ:ADHD)
davidsonregister.com - February 10 at 3:21 PM
News IconAlcobra Ltd. (NASDAQ:ADHD) hit its 52 Week high of $5.75 on Jun 1 ... - The Newburgh Press (NASDAQ:ADHD)
newburghpress.com - February 9 at 3:19 PM
News IconAlcobra Ltd. (NASDAQ:ADHD) shows monthly volitility of 10.47% - The Newburgh Press (NASDAQ:ADHD)
newburghpress.com - February 8 at 3:24 PM
News IconAlcobra Reports On Productive FDA Meeting For New Lead Product Candidate For ADHD - Clinical Leader (NASDAQ:ADHD)
www.clinicalleader.com - February 8 at 3:24 PM
feeds.benzinga.com logoAlcobra Ltd. to Release Fiscal 2016 Financial Results and Participate at the BIO CEO & Investor Conference in New York (NASDAQ:ADHD)
feeds.benzinga.com - February 8 at 8:54 AM
News IconMarket Focus: Checking in on Shares of Alcobra Ltd. (ADHD) - Rives Journal (NASDAQ:ADHD)
rivesjournal.com - February 7 at 8:25 PM
nasdaq.com logoHealth Care Sector Update for 02/07/2017: ADHD,ARWR,ATNM - Nasdaq (NASDAQ:ADHD)
www.nasdaq.com - February 7 at 8:25 PM
News IconAlcobra Ltd. (NASDAQ:ADHD) has Current Market Capitalizaion of $30.59 Million - The Newburgh Press (NASDAQ:ADHD)
newburghpress.com - February 7 at 8:25 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Reports on Productive FDA Meeting on ADAIR - StreetInsider.com (NASDAQ:ADHD)
www.streetinsider.com - February 7 at 3:25 PM
openpr.com logoAlcobra Ltd (NASDAQ:ADHD) Investor Investigation over possible Securities Laws Violation (NASDAQ:ADHD)
www.openpr.com - February 7 at 1:24 AM
rttnews.com logoADHD Abuzz, All Clear For GALE's NeuVax, FDA Lifts Clinical Hold On DCVax-L (NASDAQ:ADHD)
www.rttnews.com - February 7 at 1:24 AM
streetinsider.com logoAlcobra Ltd. (ADHD) Reports on Productive FDA Meeting on ADAIR (NASDAQ:ADHD)
www.streetinsider.com - February 6 at 8:23 PM
finance.yahoo.com logoAlcobra Reports on Productive FDA Meeting for New Lead Product Candidate for ADHD (NASDAQ:ADHD)
finance.yahoo.com - February 6 at 8:23 PM
finance.yahoo.com logo4:02 pm Alcobra announces FDA meeting on its ADAIR product candidate defined a 505(b)(2) development path, to be funded with existing cash balance, and targeting a 2H 2018 NDA submission (NASDAQ:ADHD)
finance.yahoo.com - February 6 at 8:23 PM
News IconAnalyst Views And Outlook On Two Stocks: Alcobra Ltd. (ADHD), Merrimack Pharmaceuticals, Inc. (MACK) - Post Analyst (NASDAQ:ADHD)
postanalyst.com - February 3 at 3:26 PM
News IconAlcobra Ltd. (NASDAQ:ADHD) reported Market Capitalization of 31.96 Million - The Newburgh Press (NASDAQ:ADHD)
newburghpress.com - February 3 at 3:26 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Alcobra (ADHD) Stock? - Nasdaq (NASDAQ:ADHD)
www.nasdaq.com - February 3 at 3:26 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in Alcobra (ADHD) Stock? (NASDAQ:ADHD)
finance.yahoo.com - February 3 at 3:26 PM
4-traders.com logoAlcobra Ltd : Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
www.4-traders.com - February 3 at 1:22 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ADHD)
finance.yahoo.com - February 2 at 8:20 PM
finance.yahoo.com logoFaster FDA Approval Process Could Ignite These Biotech Stocks in 2017 (NASDAQ:ADHD)
finance.yahoo.com - February 2 at 3:20 PM
finance.yahoo.com logoLifshitz & Miller Law Firm Announces Investigation of Alcobra Ltd., Egalet Corporation, Sanderson Farms, Inc., Surgical Care Affiliates, Inc., State Street Corporation, Tenet Healthcare Corp., Vista Outdoor Inc. and Zagg Inc. (NASDAQ:ADHD)
finance.yahoo.com - February 2 at 3:20 PM
News IconAverage Directional Index in Review for Alcobra Ltd. (ADHD) - Sherwood Daily (NASDAQ:ADHD)
sherwooddaily.com - February 1 at 3:24 PM
News IconNASDAQ:ADHD Investor Alert: Investigation over potential Wrongdoing at Alcobra Ltd - GroundReport (NASDAQ:ADHD)
www.groundreport.com - February 1 at 3:24 PM
News IconStock Vaulting Higher Mid-Market: Alcobra Ltd. (NASDAQ:ADHD) - Aiken Advocate (NASDAQ:ADHD)
aikenadvocate.com - February 1 at 3:24 PM
News IconIncrease in Volatility Draws Attention to Shares of Alcobra Ltd. (NASDAQ:ADHD) - Wall Street Beacon (NASDAQ:ADHD)
wsbeacon.com - February 1 at 3:24 PM

Social

What is Alcobra's stock symbol?

Alcobra trades on the NASDAQ under the ticker symbol "ADHD."

Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?

10 equities research analysts have issued twelve-month price objectives for Alcobra's stock. Their forecasts range from $1.25 to $4.00. On average, they anticipate Alcobra's share price to reach $2.16 in the next twelve months.

When will Alcobra announce their earnings?

Alcobra is scheduled to release their next quarterly earnings announcement on Wednesday, May, 17th 2017.

What are analysts saying about Alcobra stock?

Here are some recent quotes from research analysts about Alcobra stock:

  • According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (1/24/2017)

  • Piper Jaffray Companies analysts commented, "We're not particularly surprised by this outcome as the truncated dataset greatly reduced the power of this trial to demonstrate a significant impact on the CAARS. Alcobra now plans to use its ~$50M in cash to execute on a new business plan, the details of which should become available during 1Q17. We expect this could involve development of MDX in ex-US markets, or of new candidates from the company's internal pipeline or in-licensing efforts. Given the prolonged timelines to next clinical data and first revenues, as well as increased execution risk we see for this team, we are reducing our PT from $3 to $1.50, or roughly equivalent to cash/share. In advance of more details on a plan forward, we reiterate N." (1/17/2017)
  • Cantor Fitzgerald analysts commented, "an opportunity to achieve a statistically significant result with substantive hanged incorporated in the ongoing Phase III trial." Despite the failure of the first Phase III study, the analyst thought MDX had a better shot this time after implementing several protocol changes. Related Link: Goldman Initiates Specialty Pharma At Neutral, Highlights "A Confluence Of Concerns"Thriving Market ConditionsAdditionally, the "large" ADHD market has been growing at healthy levels according to the Goldstein. "The market has been fueled by the growing awareness of ADHD [...] changes in diagnosing the disorder [...] and enhanced formulations of existing stimulant base drugs," said the analyst. Alcobra's MDX was expected to be a viable competitor, able to both "cannibalize share of existing drugs as well as grow the market," (6/7/2016)

Who owns Alcobra stock?

Alcobra's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (16.25%), BROSH CAPITAL L.P. (9.00%), Broadfin Capital LLC (7.46%), Alyeska Investment Group L.P. (2.96%), Kingdon Capital Management L.L.C. (2.36%) and Royce & Associates LP (2.34%).

Who sold Alcobra stock? Who is selling Alcobra stock?

Alcobra's stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..

Who bought Alcobra stock? Who is buying Alcobra stock?

Alcobra's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Royce & Associates LP, J. Goldman & Co LP, Kingdon Capital Management L.L.C. and Broadfin Capital LLC.

How do I buy Alcobra stock?

Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alcobra stock cost?

One share of Alcobra stock can currently be purchased for approximately $1.24.

Alcobra (NASDAQ:ADHD) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Alcobra (NASDAQ:ADHD)

Earnings History Chart

Earnings by Quarter for Alcobra (NASDAQ:ADHD)

Dividend History Chart

Dividend Payments by Quarter for Alcobra (NASDAQ:ADHD)

Last Updated on 2/26/2017 by MarketBeat.com Staff